Blood line = life line?

Written byAndrea Gawrylewski

| 1 min read

Will findings by Worcester, MA-based Advanced Cell Technologies (ACT) on large-scale blood production from stem cells help the company pull in some much-needed capital? By now you've likely seen reports on a linkurl:paper;http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2008-05-157198v1 appearing today in Blood in which researchers differentiated human embryonic stem cells into oxygen-carrying blood cells, in large quantity. The results suggest it may be possible to create mass quantities of blood for transfusions and blood banks. It's a promising advance in applying embryonic stem cell technology, but what's also interesting about this study is its timing. Just linkurl:last month;http://www.the-scientist.com/blog/display/54884/ ACT stated in a Security and Exchange Commission filing that the biotech did not have funds to stay open through the end of the month. All the press "might help a little" in attracting some new investment to the company, Robert Lanza, chief scientific officer at ACT and senior author on the recent paper, told The Scientist in an Email. "But most potential investors already know what we're doing." Lanza added that the company has several papers in the pipeline. Last week, the Worcester Business Journal linkurl:reported;http://www.wbjournal.com/news41387.html that ACT had licensed some of its embryonic stem cell technology and 140 stem cell lines to Embryome, a subsidiary of BioTime Inc. The upfront payment was $250,000, with the paper reporting that ACT could stand to make $1.25 million from the deal. But Lanza told the linkurl:Boston Globe;http://www.boston.com/business/healthcare/articles/2008/08/20/stem_cells_may_bring_bottomless_blood_bank/ today that the company is still scrambling for funds, "raising small amounts of money and working on larger deals."

Blood line = life line?

The Scientist ARCHIVES

Become a Member of

Meet the Author

Andrea Gawrylewski

Related Research Resources

What Causes an Earworm?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Genome Modeling and Design: From the Molecular to Genome Scale

Screening 3D Brain Cell Cultures for Drug Discovery

Producing Tumor-infiltrating Lymphocyte Therapeutics

Weaving the Fabric of Cancer Research with Synthetic DNA

Products

Product News

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

Introducing the iQue 5 HTS Platform: Empowering Scientists with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery